The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
The National Osteoporosis Foundation (NOF) recommends considering treatment in women with a 20% or higher 10-year probability of a major fracture. However, raloxifene reduces both the risk of vertebral fractures and invasive breast cancer so that raloxifene treatment may be clinically appropriate and cost-effective in women who do not meet a 20% threshold risk. The aim of this study was to identify...
Methods: Thirteen centres (Aberdeen, Berlin, Budapest Erfurt, Graz, Harrow, Heidelberg, Leuven, Moscow, Oslo, Oviedo, Piestany and Rotterdam) contributed spine X-rays (T4-L4) to Berlin for blinded six-point quantitation and performed DXA of the hip and/or spine with cross-calibrated equipment (European Spine Phantom prototype). The Berlin data were evaluated in Manchester using 4 published algorithms,...
Low bone mass is an important risk factor for osteoporotic fracture. Wide variation across Europe has been shown in the rates of hip fracture (MEDOS) and prevalent spine deformities. (EVOS). We have investigated the effect of bone mineral density (BMD) on the risk of spine deformity.Thirteen centres randomly selected samples of 17% to 86% of their EVOS subjects for bone densitometry. Lateral spine...
We evaluated the biochemical and histomorphometric effects of a modified ADFR regimen in postmenopausal osteoporosis. Twenty women received oral phosphate (1500mg/day) for 6 months and 5 single infusions of clodronate (300mg each month) (n=10) or 5 single infusions of clodronate alone (300mg each month) (n=10).Clodronate alone significantly decreased serum alkaline phosphatase activity (-11%, p<0...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.